Wuxi PharmaTech (Cayman) Inc. operates as a pharmaceutical, biotechnology, and medical device research and development services company in China and the United States. It operates through two segments, Laboratory Services and Manufacturing Services. The Laboratory Services segment offers services for small molecules, such as synthetic chemistry, biology, medicinal chemistry, DMPK/ADME, formulation, analytical chemistry, toxicology, clinical development, bioanalytical, genomics, bioinformatics, research reagent production, and clinical services; services for discovery and development of biologics; and laboratory services, including testing services for biologics, medical devices, and combination products, as well as production of cell therapies. The Manufacturing Services segment provides manufacturing services, including development of manufacturing processes; and the production of advanced intermediates and active pharmaceutical ingredients for use by pharmaceutical companies in preclinical and clinical trials of small-molecule products, and in commercial products, as well as the production of biologic products. The company sells its products to pharmaceutical, biotechnology, and medical device companies, as well as academic institutions and non-profit organizations. Wuxi PharmaTech (Cayman) Inc. has a strategic partnership with Gilead Sciences Inc. to conduct analytical and stability studies of small-molecule new chemical entities; and strategic collaboration with Eli Lilly and Company to develop, manufacture, and commercialize a novel small molecule. Wuxi PharmaTech (Cayman) Inc. was founded in 2000 and is headquartered in Shanghai, China. As of December 10, 2015, WuXi PharmaTech (Cayman) Inc. was taken private. Wuxi PharmaTech (Cayman) Inc. operates as a subsidiary of New WuXi Life Science Limited.